Regulus jumps after data from early-stage trial for kidney disease therapy (update)
Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced ...
Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)
Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable ...
Regulus’ farabursen shows efficacy in Phase 1b kidney disease trial
Regulus (RGLS) announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the ...
American Association of Individual Investors4d
Why Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 16.28%
Regulus Therapeutics Inc.’s RGLS share price has surged by 16.28%, which has investors questioning if this is right time to ...
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to Overweight
Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an ...
Investing.com Australia3d
Regulus shares surge on Wells Fargo upgrade, clinical update
Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo (NYSE: WFC) ...
Benzinga.com3d
Regulus Therapeutics Stock Price, Quotes and Forecasts
Explore Regulus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RGLS. Regulus Therapeutics Stock Shoots Higher After Positive Results From ...